Cristal Therapeutics further strengthens its Scientific Advisory Board with appointment of Dr. Paul Lammers

Cristal Therapeutics Further Strengthens its Scientific Advisory Board with Appointment of Dr Paul Lammers

Maastricht, The Netherlands, August 9, 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced the appointment of Dr Paul Lammers to its Scientific Advisory Board (SAB). Dr Lammers, an entrepreneur in the therapeutic oligonucleotide field, will work together with other members of the Cristal Therapeutics SAB to provide strategic guidance and support the continued development of the Company’s programs, including those focused on oligonucleotide therapeutics.

Cristal Therapeutics is utilizing its proprietary CriPec® technology platform to develop a pipeline of targeted nanomedicines with superior therapeutic profiles. The Company’s lead drug candidate, CriPec® docetaxel, is in clinical Phase I studies for the treatment of solid tumours. The Company has several oncology products in preclinical discovery that incorporate therapeutic oligonucleotides. These are designed to overcome the major shortcomings of current oligonucleotide therapies, and are customised to enable the controlled and sustained release of a therapeutic payload at the disease site.

Dr Joost Holthuis, Cristal Therapeutic’s CEO and Co-founder said:

”We are pleased to welcome Paul, who has a deep scientific and clinical understanding of the therapeutic oligonucleotide arena and its market potential, to the Cristal Therapeutics’ SAB. We look forward to working with Paul. His immense expertise and experience will be very valuable as we continue to advance our preclinical oligonucleotide programs towards clinical development and maximize the potential of these therapeutic oligonucleotide modalities.”

Dr Paul Lammers is currently Chief Executive Officer of Mirna Therapeutics. Previously, he served as President of Repros Therapeutics Inc., a biopharmaceutical company, after having served for 6 years as the Chief Medical Officer for EMD Serono, Inc., the biopharmaceutical division of Merck KGaA. Having worked actively in senior roles across the Pharma and Biotech industries for the past 25 years, Dr Lammers has gained therapeutic experiences in women’s and men’s health, neurodegenerative diseases, metabolic disorders, orphan drug diseases, and oncology. Dr Lammers received a M.Sc. and M.D. from the Catholic University (Radboud University) in Nijmegen, The Netherlands.

Other members of Cristal Therapeutics SAB can be found here: (https://cristaltherapeutics.com/about-us/scientific-advisory-board/)

Boiler Plate:

Cristal Therapeutics is a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need and considerable commercial potential. The Company’s product candidates are based on its proprietary CriPec® polymeric nanoparticle technology platform, which enables the design of customised nanomedicines with superior therapeutic profiles. CriPec®-based products have the potential to provide enhanced efficacy and reduced side effect profiles, thus offering improved disease treatment.

The Company’s lead product, CriPec® docetaxel, is in clinical Phase I studies for the treatment of solid tumours. The Company has several other products in preclinical development targeting cancer and inflammatory diseases.

Cristal Therapeutics is a private company that has raised over Euro 19M to date. The Company’s headquarters and laboratories are located in Maastricht, The Netherlands.

Cristal Therapeutics raises €12.8 million in new financing round to advance novel medicines against cancer using its CriPec® nanotech platform

Cristal Therapeutics raises €12.8 million in new financing round to advance novel medicines against cancer using its CriPec® nanotech platform

  • Round led by Aglaia BioMedical Ventures and DROIA Oncology Ventures
  • Funding used:
    • to execute clinical phase Ib and phase IIa trials with CriPec® docetaxel
    • to further leverage the CriPec® platform for oligonucleotides programs from proof of concept towards investigational new drug applications

Maastricht, The Netherlands, January 19, 2017 – Cristal Therapeutics, a privately-held life sciences company developing novel nanomedicines against cancer and other diseases, today announced the closing of a €12.8 million financing round. The financing comes from a consortium headed by Dutch oncology investor Aglaia BioMedical Ventures and Belgian DROIA Oncology Ventures and was complemented by BOM, LIOF and LBDF. Existing shareholders (founders, Chemelot Ventures, BioGeneration Ventures, Utrecht University Holding, Nedermaas Hightech Ventures) also participated in the round. The new funding will be used to continue and accelerate the clinical development of Cristal Therapeutics’ lead candidate CriPec® docetaxel, by executing a clinical phase Ib trial, building the momentum for a clinical phase II trial starting later this year. Funds also allow for intensified development of Cristal’s nanotech platform for its innovative CriPec® DUO and CriPec® oligonucleotides programs.

Lead candidate
CriPec® docetaxel is Cristal Therapeutics’ lead candidate in development and represents a novel treatment approach of solid tumours. CriPec® nanoparticles with the anti-cancer drug docetaxel entrapped accumulate in tumour tissue and yield a significantly higher exposure within the tumour, thereby overcoming drawbacks of conventional docetaxel therapies. CriPec® docetaxel successfully passed various preclinical studies, demonstrating a significantly enhanced efficacy and an improved safety and tolerability profile. The candidate also successfully passed a clinical phase Ia trial in patients suffering from solid tumours where human tolerability and pharmacokinetics were assessed. Further safety and signs of efficacy will be evaluated in a clinical phase Ib study aiming to confirm the recommended phase II dose level and regimen. CriPec® docetaxel is expected to have substantial medical and commercial advantages particularly in combination therapies.

CriPec® DUO and CriPec® oligonucleotides
Cristal Therapeutics is continuously searching to broaden the application of its nanomedicine platform. The CriPec® DUO concept aims to achieve a synergistic therapeutic response of two anti-cancer drugs entrapped in one nanoparticle.

Cristal Therapeutics also applies its CriPec® platform for the delivery of oligonucleotides to intracellular targets. CriPec®’s underlying proprietary polymer and linker technology offers exciting perspectives to overcome some of the major hurdles in the oligonucleotide field.

Dr. Joost Holthuis, CEO of Cristal Therapeutics, comments on the new financing round:
‘We are thrilled to welcome high quality investors Aglaia and DROIA to Cristal Therapeutics, but also BOM, LIOF and LBDF complementing our group of investors. This clearly represents a growing commitment to nanomedicines and reflects the potential of our drug programs on the basis of the CriPec® technology.’
‘This funding comes at a time when we are taking meaningful steps forward with our clinical lead candidate CriPec® docetaxel towards achieving a better treatment for patients with advanced solid tumours. Today’s financing allows us to cover both the upcoming clinical phase Ib and IIa trial with CriPec® docetaxel and the preclinical studies for CriPec® DUO and CriPec® oligonucleotides for the period until 2019”.

Mark Krul, partner at Aglaia BioMedical Ventures, says:
‘Many cancer drugs could become more effective as a result of improved delivery of the compounds to the right cell type and cell compartment. We believe that Cristal Therapeutics’ state-of-art and highly versatile drug delivery platform has breakthrough potential in fields where drug delivery remains a key-problem, such as for nucleic acid based compounds and immuno-oncology complexes.’

Janwillem Naesens, partner at DROIA Oncology Ventures comments on their investment:
’We were impressed by the highly customizable pharmacological properties of Cristal Therapeutics’ CriPec® nanoparticles, which should enable a broad array of therapeutic applications. The delivery platform clearly stands out amongst other next-generation nanoparticles under development. With the backing of this solid investor base, the seasoned team will be able to explore the full potential of its technology.’

About Aglaia BioMedical Ventures
The Dutch venture capital firm Aglaia – through its Oncology Funds I and II – invests in ground-breaking technologies that have the potential to translate into solutions for the prevention and treatment of cancer. Aglaia is actively involved in the companies it invests in and works closely with scientists and management teams in the early stages of technological development. By translating high-potential research into commercially and clinically successful products Aglaia gives meaning to the concept of impact investing; combining financial and social returns. www.aglaia-biomedical.com

About DROIA Oncology Ventures
DROIA is a venture capital investor focusing exclusively on oncology therapeutics. Operating from Luxembourg and Belgium, DROIA invests worldwide in early-stage drug development companies that apply novel science and innovative approaches to bring highly promising drug candidates to patients. Through its experienced team of in-house scientists and drug developers, DROIA also supports young companies on scientific and development matters. Funded by private investors, DROIA is dedicated to making a difference in the fight against cancer.
www.droia.be

About Cristal Therapeutics
Cristal Therapeutics, based in Maastricht, the Netherlands focuses on the development of nanomedicines with improved therapeutic efficacy against cancer and other diseases, such as chronic inflammatory disorders, by using its patented CriPec® technology. This technology entraps existing and new drugs in polymer nanoparticles of less than 0.0001 mm diameter. These nanoparticles provide better distribution throughout the body and a more selective release of the drugs at the desired site, such as anti-cancer drugs which are preferentially targeted to tumours. Therefore, products based on CriPec® may provide enhanced efficacy and fewer side effects, thus offering improved disease treatment.

CriPec® docetaxel
CriPec® docetaxel is Cristal Therapeutics’ lead candidate in development and represents a novel treatment approach of solid tumours. CriPec® docetaxel successfully passed various pre-clinical studies, demonstrating a significantly enhanced efficacy and an improved safety and tolerability profile. The candidate also successfully passed a clinical phase Ia trial in patients suffering from solid tumours where human tolerability and pharmacokinetics were assessed. In a clinical phase Ib study further safety and signs of efficacy will be evaluated aiming to confirm the recommended phase II dose level and regimen. Later this year, Cristal Therapeutics will start a large clinical phase II study.

CriPec® DUO
CriPec® allows for the entrapment of multiple compounds (e.g. two compounds attacking the tumour through different pathways and with different toxicity) in a single nanoparticle, in a well-defined ratio and each with its individual release kinetics, with the aim to generate synergistic efficacy at an acceptable tolerability profile. To boost the selectivity, these CriPec® nanoparticles may be actively targeted to the tissue of interest.

CriPec® oligonucleotides
The use of oligonucleotides as drugs is receiving a growing interest of pharmaceutical and biotech companies. Worldwide about 150 companies are working on the development of oligonucleotides but they are all encountering similar delivery problems.
CriPec®’s underlying proprietary polymer and linker technology offers exciting perspectives to overcome some of the major hurdles in the oligonucleotide field.

Partnership
In December 2016, Cristal announced a partnership with Belgian biotech iTeos Therapeutics for the development of immuno-oncology therapeutic candidates by combining CriPec® nanoparticles with iTeos small molecule immuno-modulators with the aim of optimizing the delivery of those drug candidates into the tumour microenvironment.

===========
For more information

Cristal Therapeutics, Maastricht, The Netherlands
Joost Holthuis, PhD
Chief Executive Officer
T: +31 65 435 5535
E: joost.holthuis@cristaltherapeutics.com

LifeSpring Life Sciences Communication, Amsterdam
Léon Melens
T: +31 6 538 16 427
E: lmelens@lifespring.nl

Cristal Therapeutics and iTeos Therapeutics announce strategic partnership for the development of immuno-oncology therapeutic candidates using Cristal’s CriPec® nanotech platform

  • Initial goal to determine treatment efficacy of iTeos’ immuno-oncology drug candidates
  • Option for iTeos to license Cristal’s proprietary nanotechnology platform for development of up to three immuno-oncology therapeutic candidates

 

Maastricht, The Netherlands and Gosselies, Belgium – December 7th, 2016 – Cristal Therapeutics, a Dutch privately-held life sciences company developing novel nanomedicines against cancer and other diseases and iTeos Therapeutics SA, a Belgian privately-held biotechnology company applying its expertise in translational tumor immunology to the development of novel cancer immunotherapies, today announced a strategic partnership for the discovery, development and commercialization of optimized immuno anti-cancer drug candidates, using Cristal Therapeutics’ medicinal nanotechnology CriPec® platform.

The initial goal of this partnership is to determine the therapeutic efficacy of targeted drugs using Cristal’s CriPec® application in iTeos’ preclinical models which have been proven to be predictive in combinations of several immune activators – such as IDO1 and TDO2 – with checkpoint inhibitors. iTeos has an option to license Cristal’s proprietary nanotechnology platform to support the development and commercialization of up to three of its immune tumor-targeting programs.

CriPec®, a proprietary nanotechnology platform, consists of tuneable polymers and biodegradable drug linkers that allow for the rational design and straightforward manufacturing of custom-made nanomedicines. Applying the CriPec® platform – drugs entrapped in CriPec® nanoparticles – results in immuno nanomedicines with a superior product profile as compared to the native drug molecule. CriPec® nanoparticles improve the disposition of thousands of drug molecules per particle and allow the controlled release of these molecules specifically at the target site. This results in an improved therapeutic efficacy and tolerability.

Joost Holthuis, Cristal Therapeutics’ CEO, commented:

“This partnership with iTeos allows us to assess and demonstrate the application of our CriPec® nanoparticles, specifically in the area of novel immuno-oncology therapies. We are focused on applying our nanomedicine platform to several promising oncology indications, some of which will be evaluated for the iTeos’ development pipeline.”

Michel Detheux, , iTeos’ CEO, added:

“We are very pleased to enter into this partnership with an emerging clinical-stage nanomedicine platform company. Cristal has a strong and experienced management team, and has demonstrated the capability to quickly develop valuable therapeutic programs. We look forward to applying their platform to some of our drug candidates. We believe it has particular potential in the evolving area of causing so-called “cold tumors” – which are less responsive to checkpoint inhibitors – to become susceptible to various immuno-oncology therapies.”

About Cristal Therapeutics
Maastricht, The Netherlands based Cristal Therapeutics, is a privately-held life sciences company developing novel nanomedicines against cancer and other diseases, by using its patented CriPec® platform. CriPec® transforms drugs into polymeric nanoparticles via an innovative process. These nanoparticles provide improved distribution throughout the body. The substantial improvement of the efficacy and safety of the drugs entrapped in CriPec® nanoparticles has been demonstrated in several preclinical disease models. Cristal Therapeutics’ products in development are primarily aimed at treating patients suffering from cancer but offer also opportunities for the treatment of chronic inflammatory diseases. CriPec® docetaxel is the most advanced product candidate, and is under clinical evaluation for the treatment of solid tumors. For more information please visit www.cristaltherapeutics.com.

About iTeos Therapeutics S.A.
Based in Gosselies, Belgium, iTeos, a spin-off of Ludwig Cancer Research (LICR) and de Duve Institute (UCL), is focused on expanding the benefits of immunotherapy for cancer patients. The company is developing a proprietary pipeline targeting A2A, immune checkpoints and non-immunogenic tumors. It has licensed its IDO1 program, now in Phase 1 development, to Pfizer. iTeos’ competitive edge is in the combination of expertise in drug discovery and translational tumor immunology. The company uses a unique platform to identify rational combinations of immunotherapies and novel targets. The company is supported in part by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development). For more information please visit www.iteostherapeutics.com.

Contacts:

Joost Holthuis, CEO
Cristal Therapeutics
+ 31 43 388 5868
joost.holthuis@cristaltherapeutics.com

Michel Detheux, CEO
iTeos therapeutics
+32 71 919 933
michel.detheux@iteostherapeutics.com

For iTeos Therapeutics:

Sarah McCabe
Stern Investor Relations, Inc.
+ 1 212 362-1200
sarah@sternir.com

Jonathan Birt, Mathew Neal, Hendrik Thys
Consilium Strategic Communications
iteos@consilium-comms.com
+44 2 037 095 700

For Cristal Therapeutics:

LifeSpring Life Sciences Communication
Leon Melens
lmelens@lifespring.nl
+31 6 538 16 427